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Original Research Article
Birth Weight, Season of Birth and Postnatal Growth Do Not Predict
Levels of Systemic Inflammation in Gambian Adults
ANNA A. RICHARDS,1 ANTHONY J. FULFORD,1,2 ANDREWM. PRENTICE,1,2 AND SOPHIE E. MOORE1,2*
1Department of Population Health, Medical Research Council (MRC) International Nutrition Group,
London School of Hygiene and Tropical Medicine, Keppel Street, London, WC1E 7HT
2MRC Keneba, MRC Unit The Gambia, Banjul, The Gambia
Objectives: Studies testing whether systemic inflammation might lie on the causal pathway between aberrant fetal
and post-natal growth patterns and later cardiovascular disease have been inconclusive, possibly due to the use of sin-
gle markers of unknown predictive value. We used repeated measures of a comprehensive set of inflammatory markers
to investigate the relationship between early life measures and systemic inflammation in an African population.
Methods: Individuals born in three rural villages in The Gambia, and for whom early life measurements were
recorded, were traced (n5 320). Fasting levels of eight inflammatory markers (C-reactive protein, serum amyloid A,
orosomucoid, fibrinogen, a 1-antichymotrypsin, sialic acid, interleukin-6 and neopterin) were measured, and potential
confounding factors recorded. The association between early life measurements and systemic inflammation was
assessed using regression analysis.
Results: Levels of most markers were unrelated to early growth patterns. In analyses adjusted for age and sex, more
rapid growth between birth and 3 months of age was associated with higher levels of fibrinogen, orosomucoid, and sialic
acid. These relationships persisted after further adjustment for body mass index but after full adjustment only the
association with fibrinogen remained.
Conclusions: This study provides little evidence that size at birth or growth in early infancy determine levels of
inflammatory markers in young Gambian adults. Am. J. Hum. Biol. 25:457–464, 2013.VC 2013 Wiley Periodicals, Inc.
There is evidence that size at birth and rate of develop-
ment during early life, in particular low birth weight
(Frankel et al., 1996b; Stein et al., 1996; Forsen et al., 1997;
Rich-Edwards et al., 1997; Leon et al., 1998) and accelerated
early postnatal growth (Horta et al., 2003; Soto et al., 2003;
Jarvelin et al., 2004; Adair 2007; Hemachandra et al., 2007;
Min et al., 2007), predict increased risk of future cardiovas-
cular disease (CVD) and its associated risk factors. Despite
the large body of evidence in this field it is still not under-
stood whether size at birth, the rate of postnatal growth or a
combination of small size at birth followed by accelerated
growth is most important for determining disease risk (Gill-
man, 2002). Furthermore, the biological mechanism(s)
underpinning the associations between early life environ-
ment and later disease risk also remain unclear. Research in
the last decade has also shown that raised levels of systemic
inflammatory markers predict later morbidity and mortality
fromCVD (Danesh et al., 1998, 2000, 2004).
Previous studies investigating the relationship between
early life environment and systemic inflammation have
primarily focused on the relationship between birth
weight and C-reactive protein (CRP) (Whincup et al.,
1996; Cook et al., 2000; Gillum, 2003; Sattar et al., 2004;
Raqib et al., 2007) or fibrinogen (Barker et al., 1992; Fall
et al., 1995; Martyn et al., 1995; Frankel et al., 1996a;
Leger et al., 1997; Cook et al., 1999; Roseboom et al.,
2000). These studies, predominately in white Caucasian
populations and typically defining systemic inflammatory
status using a single measure of one inflammatory
marker, have reported conflicting results. The current
study widens the evidence base in this field by investigat-
ing whether early life variables, including early postnatal
growth, predict levels of a wide range of inflammatory
markers in Gambian adults. This is the first study to test
this hypothesis in an indigenous African population.
Furthermore, this study collects duplicate measures of
inflammatory markers to assess which marker(s) most
reliably characterises chronic systemic inflammation.
METHODS
Study population
The study population was all consenting individuals
aged 18–30 years born in three rural villages (Keneba,
Kantong Kunda, or Manduar) in West Kiang, The Gambia
(West Africa) between 1976 and 1987 and for whom birth
weight was recorded as part of the United Kingdom Medi-
cal Research Council (MRC) Keneba Antenatal Scheme.
Details of this scheme and the research setting are avail-
able elsewhere (Rayco-Solon et al., 2004). Participants
attended a study clinic at one of two MRC stations
depending on whether they lived in rural West Kiang
(MRC, Keneba) or in the urban centres near the coast
(MRC, Fajara). Logistical limitations meant that only
potential participants traced to within 90 min drive from
either of the two stations were recruited.
Additional Supporting Information may be found in the online version of
this article.
Contract grant sponsor: MRC Research Grant; Contract grant number:
G0500048; Contract grant sponsor: MRC core funding to the International
Nutrition Group; Contract grant number: MC-A760-5QX00.
*Correspondence to: Sophie Moore, MRC International Nutrition Group,
Department of Population Health, London School of Hygiene and Tropical
Medicine, Keppel Street, London, WC1E 7HT. E-mail: sophie.moore@
lshtm.ac.uk
Received 1 February 2013; Revision received 30 April 2013; Accepted 6
May 2013
DOI: 10.1002/ajhb.22413
Published online 10 June 2013 in Wiley Online Library
(wileyonlinelibrary.com).
VC 2013 Wiley Periodicals, Inc.
AMERICAN JOURNAL OF HUMAN BIOLOGY 25:457–464 (2013)
Ethical approval for this study was obtained from the
London School of Hygiene and Tropical Medicine Ethical
Committee and the joint Gambian Government / MRC
Unit The Gambia, Ethics Committee. All study partici-
pants gave informed written consent before participating.
Early life measurements
Birth weight (kg) was recorded by the resident paediatrician
or midwife to the nearest 10 g and within 72 h of birth. Gesta-
tional age was assessed using the score of Dubowitz et al.
(1970). Low birth weight (LBW) was defined as<2,500 g. Post-
natal weight was measured regularly, at postnatal clinics, to
the nearest 10 g using standard equipment; the exact timing of
measurements varied by child but date of measurement was
recorded for allweights.Growthvelocity frombirth to 3months
was calculated as the difference between population-derived
sex-specific birth weight standard deviation (SD) score and
population-derived sex-specific weight at 3 months SD score,
whereweight at 3monthswas defined as theweight nearest to
3months thatwas recorded between 2.0 and 4.0months of age.
The weight nearest 12 months that was recorded between 9.6
and 14.4 months of age was used for weight at 1 year. Hungry
(wet) season of birth was defined as a birth month between
July to December inclusive and harvest (dry) season between
January to June inclusive (Moore et al., 1999).
Systemic inflammatory markers
Blood samples were collected after an overnight fast and
then centrifuged for 20 min at 3,000 rpm and 4C within 1
h of collection and immediately frozen to 280C. Serum
samples were allowed to clot at room temperature, and then
centrifuged and processed as described for plasma. Analyses
of CRP, serum amyloid A, a 1-antichymotrypsin (ACT), oro-
somucoid, interleukin-6 (IL-6), sialic acid and neopterin,
were performed at MRC Human Nutrition Research, Cam-
bridge, UK. Fibrinogen was measured at Addenbrooke’s
Hospital Clinical Laboratory, Cambridge, UK.
CRP was measured using a high-sensitivity particle-
enhanced turbidimetric immunoassay (Dade Behring,
Milton Keynes, UK) on a Dimension ARX Analyzer (Dade
Behring, Milton Keynes, UK). The assay has a lower
detection level of 1.1 mg/l. Plasma serum amyloid A was
measured in duplicate using the enzyme-linked immuno-
sorbent assay (ELISA) principle (Anogen, Mississauga,
Canada). Fibrinogen was measured using the Clauss
assay. Plasma orosomucoid was measured using an immu-
noturbidimetric method (Sentinel, Milan, Italy) adapted
for use on the Dimension ARX Analyzer (Dade Behring,
Milton Keynes, UK). ACT was measured using an immu-
nochemical assay (Dako, Glostrup, Denmark) adapted for
use on the Hitachi 912 analyzer (Roche, Welwyn Garden
City, UK). IL-6 was measured in duplicate using a high-
sensitivity ELISA principle (Diaclone, Besanc¸on, France).
Sialic acid was measured by a colorimetric enzyme assay
(Roche, Welwyn Garden City, UK) and adapted for use on
the Hitachi 912 Analyzer (Roche, Welwyn Garden City,
UK). Serum neopterin was measured in duplicate using a
competitive enzyme immunoassay principle (BRAHMS
Atiengesellschaft, Berlin, Germany). Interassay coeffi-
cients of variation were <9.6% for all analyses.
Potential confounding factors
Anthropometry. Weight was measured to the nearest 100
g using an electronic portable scale (Chasmors, UK) and
height to the nearest mm using a portable stadiometer
(CMS Weighing Equipment Ltd, London, UK). BMI (kg/
m2) was calculated and categorized using standard cut-
offs (WHO, 2000). Waist and hip circumference (cm) were
measured to the nearest 0.1 cm. Central obesity was
defined as a waist-to-hip ratio 0.90 (men) or 0.80
(women) (Dobbelsteyn et al., 2001). Whole body composi-
tion was measured using dual energy X-ray absorptiome-
try (DXA) on a Lunar DPX1 (Lunar Corporation,
Madison WI).
Infectious disease markers. Participants were only
enrolled if considered ‘healthy’ at the time of recruitment,
based on a screening questionnaire collecting data on
recent clinic visits, current medication use, appetite and
recent weight loss. Axillary temperature was also
recorded. A thick film was prepared from whole blood to
look for the presence of malaria parasites. The remaining
whole blood was used to measure white blood cell (wbc),
lymphocyte, granulocyte and monocyte counts (109/l) and
haemoglobin (g/dl) using a Medonic CA 530 Oden 16
Parameter System Haemoglobinometer (Medonic, Stock-
holm, Sweden).
Chronic disease markers. Fasting glucose, total choles-
terol, high density lipoprotein (HDL)-cholesterol, triglyc-
eride and leptin levels were measured at MRC Human
Nutrition Research, Cambridge, UK. Plasma glucose con-
centration was measured using an adaptation of the
hexokinase-glucose-6-phosphate dehydrogenase method
(Dade Behring, Milton Keynes, UK). Impaired fasting glu-
cose (IFG) was defined by a fasting plasma glucose 6.1
and 6.9 mmol/l and type 2 diabetes by a level 7.0
mmol/l (Genuth et al., 2003). Plasma lipids were meas-
ured using enzymatic methods on a Dade Behring Dimen-
sion (Dade Behring, Milton Keynes, UK). Low density
lipoprotein (LDL)-cholesterol was derived using the Frie-
dewald equation (Friedewald et al., 1972). Leptin was
measured by ELISA (R&D Systems, Abingdon, UK). Insu-
lin was measured at Addenbrooke’s Hospital Clinical Lab-
oratory, Cambridge, UK using a time-resolved
fluoroimmunoassay (AutoDELFIA, PerkinElmer Life &
Analytical Sciences, Wallac Oy, Turku, Finland). Blood
pressure was measured using a fully automatic digital
blood pressure monitor (Omron 7051T, Omron Health-
care, IL. Hypertension in adults was defined by a systolic
blood pressure (SBP) 140 mmHg and/or a diastolic blood
pressure (DBP) 90 mm Hg (WHO, 1999).
Lifestyle measures. Questionnaire data confirmed
whether participants were still in full-time education and
their smoking status (current smoker, ex-smoker or never
smoked). Smoking status was analyzed as ever or never
smoked due to the small number of current smokers in
the study population. Additional data were collected, by a
female fieldworker, on whether women used oral or inject-
able hormonal contraceptives.
Data collection protocol
Markers of systemic inflammation and infectious dis-
ease status were assessed at two time points [baseline
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(Day 0) and 2-weeks (Day 14)]. In a random sub-sample of
15 women these levels were further assessed at Day 28 to
investigate the reliability of a single measurement to
characterise habitual systemic inflammatory status. All
other measurements were collected at baseline only. Base-
line data were collected between 23 February and 1 June,
2-week data between 9 March and 15 June and 4-week
data between 24 March and 30 March, 2006.
STATISTICAL METHODS
A total of 209 (65.3%) participants had a CRP and 266
(83.1%) an IL-6 measurement below the minimum assay
detection level (<1.1 and <0.8 pg/ml, respectively). CRP
and IL-6 were therefore analyzed as binary variables
(CRP <1.1 vs. 1.1 mg/l; IL-6 <0.8 vs. 0.8 pg/ml). Oro-
somucoid, ACT, sialic acid and neopterin were loge trans-
formed to normality. A loge transformation of serum
amyloid A failed to produce a normal distribution and it
was necessary to add 100 to each serum amyloid A value
and then take the loge transformation to obtain a normal
distribution.
The effects of potential confounding factors (listed in
Table 1) on levels of inflammatory markers were assessed
using logistic regression analysis for CRP and IL-6 and
linear regression analysis for all remaining inflammatory
markers. Population-derived SD-scores for continuous
measures of chronic and infectious disease were used
when examining their association with inflammatory
markers. This enabled direct comparison between the
effects of different measures on levels of inflammatory
markers. SD scores were generated from untransformed
data for those variables which were normally distributed
and from transformed data (loge) for those variables
which were transformed to produce a normal distribution.
All SD scores were sex-specific. SD-scores could not,
TABLE 1. Characteristics of the study population by sex at baseline
Males (n5166) Females (n5 154)
n
Median (IQR)/percent
(number) n
Median (IQR)/percent
(number)
Characteristic
Age (years) 166 22.7 (20.1, 24.2) 154 22.8 (20.3, 25.2)
Location (percentage living in rural
vs. urban area) (%)
166 15.1 (25) 154 31.8 (49)
Early life measurements
Birth weight (kg) 166 3.10 (3.03, 3.16) 154 2.87 (2.80, 2.93)
Gestational age (weeks) 136 38.9 (38.7, 39.2) 131 38.6 (38.4, 38.9)
Percent low birth weight (%) 166 8.4 (14) 154 17.5 (27)
Weight at one year (kg) 161 8.28 (8.12, 8.44) 147 7.65 (7.48, 7.82)
Change in SD-score from birth to
3 months (SD-score)
143 20.02 (20.18, 0.14) 127 20.15 (20.32, 0.03)
Percent born in hungry season 166 51.8 (86) 154 53.9 (83)
Adult adiposity
Body mass index (kg/m2) 166 20.1 (18.9, 21.1) 154 21.1 (19.6, 23.3)
Underweight/normal weight/overweight/
obese (%)a
166 19.3 / 78.9 / 1.2 / 0.6 154 10.4 / 76.0 / 12.3 / 1.3
DXA total fat (kg)b 146 4.1 (3.0, 6.0) 138 13.1 (10.5, 18.2)
Waist-to-hip ratio 166 0.76 (0.73, 0.79) 154 0.76 (0.73, 0.80)
Central obesity (%)c 166 0.6 (1) 154 15.6 (24)
Chronic disease
Systolic blood pressure (mm Hg) 166 120.2 (113.7, 127.7) 154 113.3 (108.7, 119.7)
Diastolic blood pressure (mm Hg) 166 68.7 (65.0, 75.3) 154 70.0 (64.7, 74.3)
Hypertension (%)d 166 2.4 (4) 154 3.3 (5)
Glucose (mmol/l) 166 4.8 (4.6, 5.0) 154 4.7 (4.5, 4.9)
Insulin (pmol/l) 166 37.5 (27.1, 48.9) 153 44.5 (29.8, 59.9)
Impaired fasting glucose (%)e 166 0.6 (1) 154 0.6 (1)
Type 2 diabetes (%)f 166 0(0) 154 0.6 (1)
Total cholesterol (mmol/l) 164 3.7 (3.3, 4.2) 152 4.2 (3.6, 4.7)
Triglycerides (mmol/l) 164 0.61 (0.46, 0.80) 152 0.53 (0.42, 0.64)
HDL cholesterol (mmol/l) 164 1.21 (1.06, 1.40) 152 1.42 (1.21, 1.62)
LDL cholesterol (mmol/l) 164 2.2 (1.8, 2.5) 152 2.5 (2.0, 2.9)
Infectious disease
White blood cell count (109/l) 164 4.5 (3.9, 5.2) 154 4.9 (4.3, 5.5)
Lymphocyte count (109/l) 163 2.0 (1.7, 2.5) 153 2.0 (1.7, 2.3)
Granulocyte count (109/l) 163 2.0 (1.6, 2.5) 153 2.4 (1.9, 3.0)
Monocyte count (109/l) 163 0.4 (0.3, 0.4) 153 0.4 (0.3, 0.4)
Malaria parasitaemia (%) 166 1.2 (2) 154 0 (0)
Haemoglobin (g/dl) 164 15.7 (14.7, 16.8) 154 13.7 (12.8, 14.5)
Lifestyle
Ever used tobacco regularly (%) 166 29.5 (49) 154 0 (0)
Ever attended school (%) 166 98.8 (164) 154 93.5 (144)
Hormonal contraceptive use (%) Not applicable 154 3.3 (5)
DXA5dual energy X-ray absorptiometry.
aUnderweight5body mass index (BMI) <18.5 kg/m2; normal518.5–24.9 kg/m2; overweight5 25.0–29.9 kg/m2; obese530.0 kg/m2.
bDXA measurements were not available for 36 study participants, all of whom were located in the urban coastal areas and were unable to travel to Keneba (where
the DXA machine was located) for measurements.
cCentral obesity defined as waist circumference 90.0 cm (males) or 80.0 cm (females).
dHypertension was defined as a systolic blood pressure140 mm Hg and/or a diastolic blood pressure90 mm Hg.
eImpaired fasting glucose was defined as a fasting glucose6.1 and 6.9 mmol/l.
fType 2 diabetes was defined as a fasting glucose7.0 mmol/l.
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however, be generated for anthropometric, body composi-
tion and leptin measurements as a number of these meas-
ures could not be transformed to produce the normal
distribution necessary to generate SD scores. The effect of
anthropometric, body composition and leptin measure-
ments on levels of inflammatory markers were examined
in males and females separately because of the strong
sex-differences in these measures observed within the
study population.
The associations between birth weight, weight at 1 year
and postnatal growth with levels of inflammatory
markers were analyzed using logistic regression for CRP
and IL-6 and linear regression for all remaining inflam-
matory markers according to the analytical approach
recommended by Lucas et al. (1999). This approach uses
four separate models. The ‘early model’ relates early size
(e.g. birth weight) to later outcome (e.g. adult fibrinogen
level). The ‘later model’ relates later size (e.g. BMI) to
later outcome. The ‘combined model’ is the early model
adjusted for later size. The ‘interaction model’ is the com-
bined model including an early size/later size interaction
term (e.g. birth weight*BMI). Associations between low
birth weight and season of birth with levels of inflamma-
tory markers were investigated using logistic regression
for CRP and IL-6 and linear regression for all remaining
inflammatory markers. All analyses were undertaken
twice: first, adjusting for age and sex only and second,
adjusting for all those potential confounding factors
Fig. 1. Flow chart summarising the selection of study participants.
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observed to predict levels of each inflammatory marker.
Study participants had up to three measures of each
inflammatory marker recorded at baseline (Day 0), 14
days and 28 days. Of the 320 participants for whom levels
of inflammatory markers were available at Day 0, 303
had repeat measures at Day 14 and a further 15 at Day
28. Intraclass correlation coefficients were used to gener-
ate reliability estimates for continuous inflammatory vari-
ables using all available data from Day 0, Day 14 and Day
28. In order to get the most accurate measure of systemic
inflammation (i.e. a measure that was not ‘falsely’ ele-
vated by underlying infection) the lowest level of each
inflammatory marker were used in all analyses. As oroso-
mucoid, ACT, sialic acid, neopterin and serum amyloid A
were loge transformed to normality, the b-coefficients gen-
erated from their linear regression models are presented
as a percentage unit increase; data from untransformed
variables (fibrinogen) are presented as absolute changes.
RESULTS
Selection of study participants
Figure 1 describes the selection of study participants
and lists reasons for noninclusion. A total of 781 individu-
als met the study criteria, of whom 148 were excluded
prior to tracing. Fieldworkers traced the remaining 633
eligible individuals of whom 181 were subsequently found
to be unavailable for study. Fieldworkers were able to con-
tact 86.7% (n5 392) of the 452 individuals traced of whom
72 (18.4%) declined to participate. The majority of those
who declined were male (n5 46; 63.9%). The remaining
320 individuals represent 70.8% of those traced and avail-
able for study (n5452).
Compared with nonparticipants, study participants
were younger (mean (95% confidence interval) age 22.2
(21.8, 22.5) vs 23.0 (22.7, 23.3) years; P50.0001) and a
slightly higher percentage were male (51.9 vs 45.3%;
P50.07). Mean birth weight, gestational age, change in
SD score from birth to 3 months and weight at 1 year and
percentage born during the hungry season or low birth
weight were not different between participants and
nonparticipants.
CHARACTERISTICS OF THE STUDY PARTICIPANTS
Table 1 describes the characteristics of the study popu-
lation by gender. Forty-one participants (12.8%) were
born low birth weight with a higher prevalence in female
compared with male participants (17.5 vs. 8.4%.;
P50.02). Gestational age ranged from 32.0 to 41.6 weeks
with 30 participants (11.2%) born premature (<37 weeks
gestation). The majority of participants had a BMI within
the normal range although the percentage overweight, or
centrally obese, was considerably higher in females com-
pared to males (P<0.001 for both). As expected in young
Gambian adults there was a low prevalence of hyperten-
sion (<3%), IFG (<1%) and type 2 diabetes (<1%). Less
than 1% of the study population had asymptomatic
malaria. There was a clear sex-difference in tobacco use
with no females, compared with 30% of males reporting
ever using tobacco regularly. Few women (3.3%) used hor-
monal contraceptives.
Table 2 presents the full summary statistics and reli-
ability estimates for each inflammatory marker. There
was considerable variation in the reliability estimates
between inflammatory markers; the highest estimate
(0.718) was observed for sialic acid.
Association between early life exposures and systemic
inflammation
Regression analysis adjusted for age and sex. In regres-
sion analyses, each adjusted for age and sex, there was no
evidence that birth weight, low birth weight, weight at 1
year or season of birth predicted levels of systemic inflam-
matory markers. There was evidence that a higher
change in SD score from birth to 3 months was associated
with higher levels of fibrinogen, orosomucoid and sialic
acid but no association was observed with the remaining
five markers. For each one unit increase in change in SD
score fibrinogen levels increased by 0.11 g/l (95% CI 0.03–
0.18 g/l; P50.004), orosomucoid levels increased by 3%
(95% CI 0.4–5.4%; P5 0.02) and sialic acid levels by 2%
(95% CI 1–4%); P50.003).
Regression analysis fully adjusted for potential confounding
factors. For each inflammatory marker, multiple regres-
sion analyses were used to adjust for measures of location,
chronic disease, infectious disease and lifestyle (as listed
in Table 1) that predicted levels of that inflammatory
marker. To facilitate comparisons with other studies, and
because data were available for all study participants,
BMI was used as the primary measure of adult adiposity.
After full adjustment there was no association between
TABLE 2. Summary statistics and reliability estimates of inflammatory markers for the total population
Inflammatory marker n Mean (SD) Range n
Reliability
estimate (SE)
95 % confidence interval
of the reliability estimate
Serum amyloid A (ng/ml)a 320 1308 (628, 2488) 0.55, 16000 641 0.498 (0.042) 0.416, 0.581
Fibrinogen (g/l) 320 2.8 (0.6) 1.19, 5.61 643 0.405 (0.047) 0.313, 0.496
Orosomucoid (mg/dl)a 320 68.8 (59.2, 78.4) 39.0, 157.7 640 0.688 (0.030) 0.630, 0.746
a 1-antichymotrypsin (g/l)a 320 0.28 (0.25, 0.30) 0.19, 0.60 643 0.630 (0.034 0.564, 0.696
Sialic acid (mg/dla 320 66.4 (61.2, 72.4) 46.8, 109.6 643 0.718 (0.027) 0.665, 0.771
Neopterin (nmol/l)a 320 7.45 (6.40, 8.63) 4.18, 18.25 633 0.532 (0.041) 0.453, 0.612
Inflammatory marker n Percent (n) Rangeb
C-reactive protein< 1.1 (mg/l) 320 65.3 % (209) 0.55, 13.6
Interleukin-6< 0.8 (pg/ml) 320 83.1 % (266) 0.4, 15.5
IQR5 inter-quartile range; SD5 standard deviation.
aLogged data used to report geometric mean (inter-quartile range).
bRange of levels in those individuals categorised as having a C-reactive protein level 1.1 mg/l and an interleukin-6 level0.8 pg/ml.
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birth weight, low birth weight, weight at 1 year or season
of birth and levels of inflammatory markers. After full
adjustment, early postnatal growth still predicted higher
levels of adult fibrinogen (0.10 (95% CI 0.03–0.16) g/l;
P50.007) and showed a weak positive association with
sialic acid (1.00 (95%-0.05 to 2.92)%; P50.06) but any
association with orosomucoid levels was removed. Table 3
reports the relationship between early postnatal growth
and fibrinogen according to the analytical approach recom-
mended by Lucas and colleagues. Supporting Information
Tables S1-A–D and S2-A–D present the regression analy-
ses for four selected markers (CRP, orosomucoid, sialic acid
and IL-6) by birth weight and early postnatal growth.
There was no evidence that adjusting for DXA meas-
ures of adiposity altered the association between post-
natal growth and levels of inflammatory markers (data
not shown). The only exception to this was that adjust-
ment for DXA, total or percent fat, rather than BMI,
forced the association between postnatal growth and lev-
els of sialic acid toward the null.
DISCUSSION
The current study aimed to test the hypothesis that sys-
temic inflammation is young adulthood is predicted by
early life exposures. Using a comprehensive set of
markers in a cohort of 320 young Gambian adults, we
have found little evidence for an effect of a number of
early life parameters on later inflammatory status. This is
the first published study to investigate this association in
an indigenous African population. The inclusion of a
range of early life measures, in particular early postnatal
growth, and a large and varied number of markers to
assess systemic inflammation considerably widens the
evidence base in this field.
To date, the only published data supporting an associa-
tion between prenatal exposures and systemic inflamma-
tion comes from studies looking at the relationship
between birth weight and either CRP or fibrinogen. Previ-
ous studies in infants and young children have reported
no association between birth weight and levels of CRP
(Cook et al., 2000; Gillum, 2003; Oldroyd et al., 2009),
although one study was hampered by the failure to use a
high-sensitivity assay (Gillum, 2003). Studies in adults,
including data from 5,849 Finnish men and women aged
31 years (northern Finland 1966 Birth Cohort; Tzoulaki
et al., 2008) and 1,603 middle-aged Scottish adults (Sattar
et al., 2004) have reported that, after adjustment for con-
founding factors, lower birth weight was associated with
higher levels of CRP. A separate analysis of the northern
Finland Birth Cohort also reported that lower birth
weight predicted higher adult total leukocyte count
(Canoy et al., 2009). Likewise, data from the Philippines
shows that birth weight was negatively associated with
CRP in adulthood (McDade et al., 2010, 2012), A number
of previous studies have investigated the association
between birth weight and fibrinogen (as a measure of
CVD risk). The findings from previously published studies
in adults are inconsistent (Martyn et al., 1995; Frankel
et al., 1996a) but in line with this study, the majority have
reported no association (Barker et al., 1992; Leger et al.,
1997; Roseboom et al., 2000).
Few studies have investigated the association between
postnatal growth and systemic inflammation. Data from
3,827 adults in the 1982 Pelotas (Brazil) birth cohort sug-
gest that rapid weight gain across the life course predicts
higher CRP at age 23 years (Nazmi et al., 2009). In the
northern Finland birth cohort, participants with highest
tertile body mass index (BMI) at 31 years and lowest tertile
birth weight had the highest average CRP levels (Tzoulaki
et al., 2008). It has been suggested that the association
between low birth weight and increased CVD risk factors
in later life may not be a result of low birth weight per se
but the subsequent rapid postnatal growth (Kuh and Ben-
Shlomo, 1997). The potential mechanisms explaining any
association between rapid postnatal growth and adult sys-
temic inflammation are not understood and cannot be
tested by the current study design. A series of systematic
reviews have reported that rapid catch-up growth is a risk
factor for later obesity (Baird et al., 2005; Monteiro and
Victora, 2005; Ong and Loos, 2006). One potential mecha-
nism, therefore, is that later adiposity determined by
catch-up growth explains any association between rapid
postnatal growth and levels of inflammatory markers. In
the current study, adjustment for BMI did not alter the
association between postnatal growth and fibrinogen; sug-
gesting that in this study population catch-up growth,
independent of adult adiposity, was important. A second
TABLE 3. Linear regression associations between postnatal growth (change in standard deviation (SD)-score from birth to three months) and
adult levels of fibrinogen)
Postnatal growth (change in SD-
score from birth to 3 months) Body mass index (kg/m2) Interactionb
Regression modela n b-coefficient (95 % CI) P-value b-coefficient (95 % CI) P-value b-coefficient (95 % CI) P-value
(A) Adjusted for age and sex
Early 270 0.11 (0.03, 0.18) 0.004
Later 270 0.04 (0.01, 0.07) 0.004
Combined 270 0.10 (0.03, 0.17) 0.006 0.04 (0.01, 0.07) 0.01
Interactionb 270 0.01 (20.02, 0.04) 0.42
(B) Adjusted for age, sex and all factors which predicted fibrinogen levelsc
Early 263 0.10 (0.03, 0.16) 0.007
Later 263 0.04 (0.01, 0.06) 0.01
Combined 263 0.09 (0.02, 0.16) 0.008 0.04 (0.01, 0.06) 0.01
Interactionb 263 0.01 (20.01, 0.04) 0.40
b-coefficient [95% confidence interval (CI)] were calculated using linear regression and represent the increase in fibrinogen for each one unit increase in the explana-
tory variable.
aThe early model relates early size (postnatal growth) to later outcome (adult fibrinogen). The later model relates later size (adult body mass index) to later outcome
(adult fibrinogen). The combined model is the early model adjusted for later size (adult body mass index).
bThe interaction model is the combined model including an early size/later size interaction term (postnatal growth3 body mass index).
cFurther adjusted for HDL-cholesterol, white blood cell, granulocyte and monocyte counts, malaria parasitaemia and tobacco use.
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potential mechanism is that rapid catch-up growth and
raised levels of fibrinogen and sialic acid arise from a com-
mon genotype. However, there is currently no evidence in
support of this hypothesis, and it cannot be tested from the
data collected in the current study.
A number of published reports have tested the repeat-
ability of CRP within individuals across longitudinal col-
lections (e.g., Macy et al., 1997; McDade et al., 2010;
Ockene et al., 2001; McDade et al., 2012). However, only
one previous study has collected repeat measures of a
range of inflammatory markers to assess which most reli-
ably characterizes systemic inflammation (Browning
et al., 2004). Browning et al. (2004) compared three repeat
measures of a range of cytokines and acute phase
response markers (including CRP) in 15 overweight white
Caucasian UK women over a 6 month period and con-
cluded that IL-6 and sialic acid were best at characteris-
ing systemic inflammation with a single measure. In the
current study CRP and IL-6 were analyzed as binary vari-
ables and the repeatability of both measures could not be
assessed. However, of the six remaining inflammatory
markers studied sialic acid had the highest repeatability
co-efficient. The observation, in two different populations,
that a single measure of sialic acid provides a reliable
measure of habitual systemic inflammation gives further
weight to the conclusion by Browning et al., that future
studies should consider using sialic acid as a measure of
systemic inflammation. Sialic acid is not an acute phase
protein but the terminal glycoprotein found in a number
of acute phase proteins. It has been estimated that these
glycoproteins account for approximately 70% of the total
sialic acid concentration (Lindberg et al., 1993). Browning
et al. argue that sialic acid may therefore provide an
“integrated measure of the inflammatory response” which
is “less prone to the day-to-day variability of individual
markers”; there is no reason why this explanation is not
pertinent to the current (and other) study populations.
The primary strength of the current study is the collec-
tion of data on eight inflammatory markers allowing a
more detailed investigation into the association between
early life parameters and systemic inflammation than
previous studies. Furthermore, the collection of repeat
samples of inflammatory markers enabled the reliability
of a single measure to be assessed for the first time in an
indigenous African population. The very low incidence of
risk factors for CVD in this population limited the possi-
bility that systemic inflammation was elevated due to
clinical or subclinical atherosclerosis.
One of the difficulties of measuring systemic inflamma-
tion in an African, compared with UK, population is that
levels of markers may be elevated as a result of infectious
disease. Levels of infectious disease in the study population
were limited by carrying out data collection in the dry sea-
son (November to May) [the rains from June to October
coincide with an increase in disease transmission (Brew-
ster and Greenwood, 1993)]. The prevalence of malaria
parasitaemia and incidence of elevated levels of inflamma-
tory markers indicated that the population under investi-
gation were healthy at the time of study (for example, only
2% of individuals had CRP levels> 6 mg/dl).
The majority of published data linking inflammation to
later CVD comes from industrialised settings. The possibil-
ity exists, therefore, that within rural African or other
indigenous populations inflammation may not always be a
risk factor for CVD. In the Tsimane tribe from Bolivia, for
example, markers of infection and inflammation were
much higher than among comparable US adults (Gurven
et al., 2009). Such data suggest that inflammation in such
settings may be offset by other factors such as an active
lifestyle and favorable body mass, and hence not result in
morbidity or mortality from chronic degenerative diseases.
A critical weakness of the study is that the population
measured represents only 41% of those who met the ini-
tial study criteria (n5781). Comparisons between partici-
pants and nonparticipants however suggest no differences
between the two groups in the exposure variables avail-
able for analysis. In addition, it is important to highlight
that this study was investigating comparisons within-
subjects and it is unlikely that in nonparticipants any
associations between early life factors and levels of
inflammatory markers would be in the opposite direction
to that observed in participants.
It has been suggested that the association between birth
weight and other determinants of cardiovascular disease
(e.g. blood pressure) amplifies with age; the relatively young
age of the study population (19–30 years) may have pre-
vented any association between early life events and levels
of inflammatory markers being observed. Furthermore, the
study participants were relatively lean and therefore under-
lying associations may exist but remain hidden.
A technical limitation of the study design was that
despite using high sensitivity kits the CRP and IL-6
assays were not sufficiently sensitive in the lower ranges.
In total, 65 and 83% of participants had levels of CRP and
IL-6 below the assay ranges, respectively; CRP and IL-6
were subsequently analyzed as binary variables which
limited the power to observe any association with early
life factors. No evidence-base was available with which to
decide the cut-offs for generating the binary variables. It
is possible that the cut-offs used in this study (above and
below the lowest assay cut-off) also limited observations
on the effect of early life factors on levels of CRP and IL-6.
CONCLUSIONS
The main hypothesis of this study was that early life pro-
gramming of systemic inflammation was a mechanism to
explain the association between poor early life growth and
increased risk of adult CVD; this study provided little evidence
to support this hypothesis among young, leanGambians.
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